VRM
GNCA

Vectors Research Management’s Genocea Biosciences, Inc. GNCA Stock Holding History

Vectors Research Management’s Portfolio GNCA Stock Details GNCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-6,000
Closed -$7K – 603
2021
Q4 		$7K Hold
6,000
– – ﹤0.01% 476
2021
Q3 		$12K Buy
6,000
+1,000
+20% +$1.97K ﹤0.01% 353
2021
Q2 		$12K Buy
+5,000
New +$12.1K ﹤0.01% 373

Other funds holding GNCA

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Vectors Research Management's GNCA Position: Q1 2022 in Review

Vectors Research Management sold out of Genocea Biosciences, Inc. (GNCA) in Q1 2022, closing a stake of 6,000 shares — an estimated $7K sold.

Vectors Research Management first reported a position in GNCA in Q2 2021 and held it in 3 quarters. The position peaked at $12K in Q3 2021. 40 funds tracked by Wall St. Rank hold GNCA as of Q1 2022.

  • Vectors Research Management reported no remaining Genocea Biosciences, Inc. position as of Q1 2022 after selling out during the quarter.
  • Vectors Research Management sold 6,000 Genocea Biosciences, Inc. shares in Q1 2022, an estimated $7K.
  • Vectors Research Management first reported a position in Genocea Biosciences, Inc. in Q2 2021 and held it in 3 quarters.
  • Vectors Research Management's Genocea Biosciences, Inc. position peaked at $12K in Q3 2021.
  • 40 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q1 2022.

Based on Vectors Research Management's 13F filing for Q1 2022, filed 16 May 2022.